This is a routine lender-facing investor presentation with no new material financial guidance or earnings. Monitor for the completion of the senior credit facility refinancing and the SurgiMend relaunch in Q4 2026 as the next key catalysts.
Price Chart
Executive Summary
Integra LifeSciences filed an 8-K furnishing an updated investor presentation for use in connection with its previously-disclosed plans to refinance its outstanding senior credit facility in 2026. The presentation highlights LTM Q2 2026 revenue of $1,648M (up 1.6% YoY), Adjusted EBITDA of $337M (up 11.8% YoY), and a key inflection point as FDA-mandated manufacturing remediations near completion, with the new Braintree facility operational and SurgiMend relaunch on track for Q4 2026. The filing is a routine lender-facing update with no new material financial disclosures or guidance changes.
Key Facts
- LTM Q2 2026 revenue of $1,648M, up 1.6% YoY
- LTM Q2 2026 Adjusted EBITDA of $337M, up 11.8% YoY, representing a 20.5% margin
- LTM Q2 2026 free cash flow of $26M, an improvement of $57M YoY
- Net leverage decreased from 4.5x (YE 2025) to 4.1x (Q2 2026)
- Braintree facility became operational in Q2 2026; on track for commercial revenue in Q4 2026
- SurgiMend relaunch anticipated in Q4 2026
- All warning letter commitments on track to be completed in 2026
- Presentation furnished for use in connection with plans to refinance outstanding senior credit facility
Financial Impact
LTM Q2 2026 revenue $1,648M; Adjusted EBITDA $337M; Free cash flow $26M
Risk Factors
- Execution risk on remaining FDA remediation milestones and SurgiMend relaunch timeline
- Elevated net leverage at 4.1x limits financial flexibility
- Ongoing transition costs and remediation spend may pressure near-term margins
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000917520-26-000061 |
| Document: iart-20260908.htm | 0000917520-26-000061 |
| Document: 0000917520-26-000061-index-headers.html | 0000917520-26-000061 |
| Document: 0000917520-26-000061-index.html | 0000917520-26-000061 |
| Document: 0000917520-26-000061.txt | 0000917520-26-000061 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 8-K | $11.84 | awaiting T+5 | — | $12.13 (−2.41%) |
Oct 19, 2026 6d ago | 8-K | $13.33 | awaiting T+5 | — | $12.13 (−9.04%) |
Oct 14, 2026 12d ago | Court Ruling | $13.53 $12.33 | ▼ −8.91% | ▼ −7.89% | $12.13 (−10.38%) |
Oct 13, 2026 12d ago | 3 | $13.18 $11.84 | ▼ −10.13% | ▼ −10.59% | $12.13 (−7.97%) |
Oct 9, 2026 16d ago | 8-K | $13.98 $13.45 | ▲ +3.79% | ▲ +2.30% | $12.13 (+13.27%) |
Oct 6, 2026 20d ago | Press Release | $13.32 | awaiting T+5 | — | $12.13 (−8.97%) |
Oct 2, 2026 24d ago | 8-K | $12.68 $13.44 | ▼ −5.99% | ▼ −4.83% | $12.13 (+4.38%) |
Oct 2, 2026 24d ago | Press Release | $12.68 $13.44 | ▼ −5.99% | ▼ −4.83% | $12.13 (+4.38%) |
Sep 8, 2026 6w ago | 8-K | $16.26 $15.71 | ▼ −3.38% | ▼ −2.72% | $12.13 (−25.43%) |
May 8, 2026 24w ago | 8-K | $13.97 $14.11 | ▲ +1.00% | ▲ +1.09% | $12.13 (−13.21%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers